FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors - Wikidata - awgldk - TriplyDB

FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors

FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors

http://www.wikidata.org/entity/Q28368421

about

Blood cells: an historical account of the roles of purinergic signalling GPIIb-IIIa antagonists cause rapid disaggregation of platelets pre-treated with cytochalasin D. Evidence that the stability of platelet aggregates depends on normal cytoskeletal assembly The birth and postnatal development of purinergic signalling Activity of adenosine diphosphates and triphosphates on a P2Y(T) -type receptor in brain capillary endothelial cells The C6-2B glioma cell P2Y(AC) receptor is pharmacologically and molecularly identical to the platelet P2Y(12) receptor Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice ADP receptor antagonists as antiplatelet therapeutics.Nomenclature and classification of purinoceptors.ADP-induced bladder contractility is mediated by P2Y12 receptor and temporally regulated by ectonucleotidases and adenosine signaling.P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.P1,P4-dithio-P2,P3-monochloromethylene diadenosine 5',5'''-P1,P4-tetraphosphate: a novel antiplatelet agent.Modelling the P2Y purinoceptor using rhodopsin as template Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets.Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.Nucleotides as extracellular signalling molecules.Development of a comprehensive set of P2 receptor pharmacological research compounds PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors.Purinoceptors: from history to recent progress. A review.Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation.Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum The composition of the platelet cytoskeleton following activation by ADP: effects of various agents that modulate platelet function.Microglia P2Y13 Receptors Prevent Astrocyte Proliferation Mediated by P2Y1 Receptors.

P2860

Q26799623-E6909789-CC8E-4050-AEFD-26B4CDDA793C Q28247914-F89EF5A7-202F-4823-AEC4-F59B9575E184 Q28277866-6ED450BD-179E-4818-81DB-33B486CF63D8 Q28345855-E1A40CDE-0F20-44F1-B026-4E11CDCF4E4A Q28366572-9E50FB35-99AC-4E89-9B28-0629825E273A Q28367651-4D8F4217-D4E4-44C5-BABC-588ED87BB8E6 Q28367792-D3013248-0A4A-4910-A149-BA4833AD21AA Q28578957-229FE2C1-6450-45BA-B240-1E0BE4A10271 Q30486707-53545330-C606-46EB-9C6F-1E6F1AE3E0F0 Q33903557-EFB82E6B-3E21-46E4-917F-13EEAFBDF095 Q34275908-ED620B34-3648-41E8-BAC0-6419ADF82CFF Q34324355-8CA58A34-725E-4E28-B352-8652AE6BE66E Q34512888-2BBB15A7-886A-4F46-868A-4E2AEC499396 Q35027546-AF80700D-E0A8-48AE-AEBA-7B554CC5B2B3 Q36108984-4BAB0130-8048-4642-893D-C57D0741ED13 Q36251014-35866BB0-EFF1-4AE3-95DB-AAB356F06262 Q36895115-D8EA39BD-5456-404C-9E8F-66266A6A4BC3 Q37509443-41600164-D985-4183-84A6-B1B6D6DD3C49 Q40536880-D213127B-4B5B-4786-9B99-3653BD8DACA4 Q40643618-66FEFA81-B051-4502-B417-A3AC94DF203D Q41194842-A59D700A-C0A8-423F-8CEC-745DD85CB63C Q41255014-4CB4DDF6-8171-46B0-B502-1C7572CF27C3 Q41821168-04AE60C1-9C4E-4B8D-A3CD-A3AED45DA896 Q42141062-C792A07B-4A98-4C0C-B110-56A2821DDE48 Q42708996-DA9F6040-7674-4C80-BA90-4C70621FC1BD Q47777075-EAD9BAE3-2F3A-4A2F-8D3D-FB7490E66BDD Q54961702-1A4708BE-9CC1-4832-87E9-95ACBD9F5DE3

P2860

FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors

http://www.wikidata.org/entity/Q28368421

description

1994 nî lūn-bûn

@nan

1994 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1994 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

name

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@ast

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@en

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@nl

type

label

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@ast

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@en

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@nl

prefLabel

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@ast

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@en

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@nl

P1433

Q28368421-43093D0E-06B8-433B-BBF9-EA0889900265

P1476

Q28368421-21FAA107-7B9E-4622-B847-8FDEA455AC03

P2093

Q28368421-64965B0C-59FB-4D71-A506-17441C8E470B

Q28368421-8F63FF4C-9D93-4391-8B87-866136D7A00E

Q28368421-A45F597C-22D3-49DB-90E3-0F8ADF222A91

Q28368421-E55E6B8C-F838-4CDA-80C1-B1B5C8F2CBA6

Q28368421-F51DF453-220E-4D22-8324-E720CB5B8FD2

P2860

Q28368421-3074F48C-C053-4FF0-A0BC-741EC97CB0C0

Q28368421-34C8DD32-C5AD-4A63-8A59-2660D8616E23

Q28368421-3E94361B-26FD-40F7-AE37-7E883EEB2CEB

Q28368421-3EC026F9-63FB-44E1-B957-3C4E4F45EDE2

Q28368421-459084FC-F4CB-4611-915A-C91268096147

Q28368421-8985C355-D679-4DC5-A30E-74B174FCDB88

Q28368421-979D7152-3DE1-4A26-9692-C73E5435C313

Q28368421-A325AC15-4459-4D03-B022-19C30E5236D3

Q28368421-AEDB4D1D-54CE-459F-9BD7-CA0BBF5C4E8B

Q28368421-BB827F9B-88E9-4E50-AD9C-E55E2D2DDA57

P304

Q28368421-59CD7BE7-14F3-4E7D-9E94-59E34B99553C

P31

Q28368421-54873EA9-71B5-47F1-B8C2-67ACB6E0799B

P356

Q28368421-8CA2AEF9-D060-4B1E-9CE1-11AE0E8BE401

P407

Q28368421-1F3223E8-EB6F-4437-AB06-ADD3363046BD

P433

Q28368421-D73EC2F1-4F88-40B0-838C-2DFDEEDDA5AD

P478

Q28368421-B7AA476C-EC48-4ED1-ADD9-8E92D5621915

P577

Q28368421-38A02CE9-E298-4403-B1F8-60BC0B3E3C9D

P5875

Q28368421-CA782C53-B3E8-4D6B-A443-B8A764B285B8

P698

Q28368421-1477D26E-34A4-4986-94A6-F2156F557494

P932

Q28368421-4149A5F4-993F-4D9B-8A02-D9EA7BEECA7C

P356

J.1476-5381.1994.TB17100.X

P1433

British Journal of Pharmacology

P1476

FPL 66096: a novel, highly pot ...... man platelet P2T-purinoceptors

@en

P2093

A H Ingall

http://www.w3.org/2001/XMLSchema#string

P A Cage

http://www.w3.org/2001/XMLSchema#string

P Leff

http://www.w3.org/2001/XMLSchema#string

R G Humphries

http://www.w3.org/2001/XMLSchema#string

W Tomlinson

http://www.w3.org/2001/XMLSchema#string

P2860

The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist

Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria

Some quantitative uses of drug antagonists

Subtypes of P2-purinoceptors. Studies using analogues of ATP.

Adenosine antagonists.

Is there a basis for distinguishing two types of P2-purinoceptor?

Extracellular ATP: effects, sources and fate.

Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors.

Specific but noncompetitive inhibition by 2-alkylthio analogues of adenosine 5'-monophosphate and adenosine 5'-triphosphate of human platelet aggregation induced by adenosine 5'-diphosphate.

The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation.

P304

1057-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1476-5381.1994.TB17100.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

1994-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15340077

http://www.w3.org/2001/XMLSchema#string

P698

7858849

http://www.w3.org/2001/XMLSchema#string

P932

1510445

http://www.w3.org/2001/XMLSchema#string